JP2020508645A - 抗cd47抗体およびその使用 - Google Patents
抗cd47抗体およびその使用 Download PDFInfo
- Publication number
- JP2020508645A JP2020508645A JP2019541431A JP2019541431A JP2020508645A JP 2020508645 A JP2020508645 A JP 2020508645A JP 2019541431 A JP2019541431 A JP 2019541431A JP 2019541431 A JP2019541431 A JP 2019541431A JP 2020508645 A JP2020508645 A JP 2020508645A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- acid sequence
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims abstract description 135
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims abstract description 129
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 32
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 32
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 32
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 272
- 239000012634 fragment Substances 0.000 claims description 188
- 230000027455 binding Effects 0.000 claims description 182
- 239000000427 antigen Substances 0.000 claims description 122
- 102000036639 antigens Human genes 0.000 claims description 121
- 108091007433 antigens Proteins 0.000 claims description 121
- 210000004027 cell Anatomy 0.000 claims description 112
- 238000000034 method Methods 0.000 claims description 70
- 206010028980 Neoplasm Diseases 0.000 claims description 58
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 41
- 210000002540 macrophage Anatomy 0.000 claims description 38
- 206010057249 Phagocytosis Diseases 0.000 claims description 33
- 230000008782 phagocytosis Effects 0.000 claims description 33
- 238000006467 substitution reaction Methods 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 28
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 27
- 210000004881 tumor cell Anatomy 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 210000005253 yeast cell Anatomy 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 13
- 230000037430 deletion Effects 0.000 claims description 13
- 238000003780 insertion Methods 0.000 claims description 12
- 230000037431 insertion Effects 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000001737 promoting effect Effects 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 229960004641 rituximab Drugs 0.000 claims description 3
- 229960000575 trastuzumab Drugs 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 33
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract description 19
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract description 19
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 238000010586 diagram Methods 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 210000003743 erythrocyte Anatomy 0.000 description 23
- 238000011282 treatment Methods 0.000 description 20
- 102000025171 antigen binding proteins Human genes 0.000 description 18
- 108091000831 antigen binding proteins Proteins 0.000 description 18
- 230000002776 aggregation Effects 0.000 description 17
- 238000004220 aggregation Methods 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 101150036449 SIRPA gene Proteins 0.000 description 15
- 230000035931 haemagglutination Effects 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 12
- 102000044459 human CD47 Human genes 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000007614 Thrombospondin 1 Human genes 0.000 description 5
- 108010046722 Thrombospondin 1 Proteins 0.000 description 5
- 230000004520 agglutination Effects 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229920001222 biopolymer Polymers 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 102000006355 CD47 Antigen Human genes 0.000 description 3
- 108010058590 CD47 Antigen Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 108010004469 allophycocyanin Proteins 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- JGPOSNWWINVNFV-UHFFFAOYSA-N carboxyfluorescein diacetate succinimidyl ester Chemical compound C=1C(OC(=O)C)=CC=C2C=1OC1=CC(OC(C)=O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O JGPOSNWWINVNFV-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000005305 interferometry Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940125645 monoclonal antibody drug Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical compound C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- AETVBWZVKDOWHH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylazetidin-3-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CN(C1)CC AETVBWZVKDOWHH-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241001424309 Arita Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000046699 human CD14 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000005381 magnetic domain Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
から成る群より選択された1〜3つのHCDRs;およびB)下記の軽鎖相補性決定領域(LCDRs)の群:(i) 配列番号23および24のアミノ酸配列を含むLCDR1、(ii) 配列番号25と26のアミノ酸配列を含むLCDR2、(iii) 配列番号27, 28, 29および30のアミノ酸配列を含むLCDR3、および(iv) 少なくとも1アミノ酸でかつ多くても5アミノ酸のアミノ酸置換(例えば保存的置換)、欠失もしくは挿入を含む、前記(i), (ii)および(iii)に記載のLCDRsから成る群より選択された1〜3つのLCDRsを含むまたはから成り、ここで改変されたCDRsを含む前記抗CD47抗体は、CD47に結合する能力をまだ保有している。
幾つかの実施形態では、本発明により提供される抗CD47抗体またはその抗原結合性断片は、驚くべきことに、対照抗体と比較して腫瘍の増殖を効果的に阻害することができる。
1.1 定義
VL中の第24〜34位(LCDR1)、第50〜56位(LCDR2)、および第89〜97位(LCDR3)、並びにVH中の第27〜35位(HCDR1)、第50〜65位(HCDR2)、および第93〜102位(HCDR3)。
1.2 本発明の抗CD47抗体
一態様では、本発明は、上述した抗CD47抗体またはその断片のいずれかをコードする核酸を提供する。該核酸は、抗体の軽鎖および/または重鎖可変領域を含むアミノ酸配列、または抗体の軽鎖および/または重鎖を含むアミノ酸配列をコードする。
本発明は更に、CD47に結合する1以上のモノクローナル抗体またはそれの免疫学的活性断片を含む医薬組成物を提供する。本発明で提供される抗CD47抗体または医薬組成物は、担体、賦形剤、および同時投与用製剤に適する他の剤の中に製剤化することができ、それにより輸送、伝達、寛容性などの改善をもたらすことができる。
一態様では、本発明は、対象におけるSIRPαへのCD47の結合を阻害するおよび/または拮抗する方法であって、本明細書に記載の抗CD47抗体またはその断片のいずれかの有効量を該対象に投与することを含む方法に向けられる。別の態様では、本発明は、本明細書に記載の抗CD47抗体またはその断片のいずれかの有効量を該対象に投与することを含む、対象における食細胞の貪食を促進する方法に向けられる。一態様では、本発明は、治療標的であるCD47関連疾患を治療する方法であって、対象に本開示の抗CD47抗体またはその断片のいずれかの有効量を投与することを含む方法に向けられる。一態様では、本発明は、SIRPαへのCD47の結合を排除、阻害または減少させることにより任意の疾患または障害を抑制、遅延、阻害または予防することができる方法に向けられる。別の態様では、本発明は、必要とする対象において癌または腫瘍を治療する方法であって、本発明の抗CD47抗体またはその断片を該対象に投与することを通して、該対象の癌または腫瘍の症状を軽減するため、および該対象において癌または腫瘍の再発を回避するための方法を提供する。
投与は適当な経路を介することができ、投与の短期または長期性質にある程度依存するが、注射、例えば静脈注射または皮下注射によることができる。限定されないが、様々な時点に渡る単回または多数回投与、ボーラス投与およびパルス注入をはじめとする様々な投薬スケジュールが本発明で意図される。
貪食作用を促進するSIPRαとのCD47の相互作用を遮断する当該技術分野で開示されているほとんどの抗体が明白な細胞凝集を生じるとすると、マクロファージ貪食を効果的に促進することができないだけでなく、細胞の凝集にも至らない新規な抗CD47抗体の大きな必要がなおある。この点での要望は、本出願明細書中に開示される抗CD47抗体により満たされ、貪食を促進するのに効果的であり、抗腫瘍成長および腫瘍の除去という優れた効果を発揮するだけでなく、治療効果を発揮しながら明白な細胞凝集を引き起こさず、それにより有意に減少した副作用を有する。
1.6 診断および検出のための方法と組成物
1.7 本発明の典型的抗CD47抗体の配列
ADI26624−IgG4
HCのアミノ酸配列(配列番号74):
HCのアミノ酸配列(配列番号76)
ADI29340−IgG4
HCのアミノ酸配列(配列番号77)
ADI26630−IgG4
HCのアミノ酸配列(配列番号78)
HCのアミノ酸配列(配列番号80)
ADI29349−IgG4
HCのアミノ酸配列(配列番号81)
ADI26591−IgG4
HCのアミノ酸配列(配列番号82)
HCのアミノ酸配列(配列番号84)
ADI30793−IgG4
HCのアミノ酸配列(配列番号85)
HCのアミノ酸配列(配列番号87)
ADI26624−IgG1
HCのアミノ酸配列(配列番号88)
ADI29336−IgG1
HCのアミノ酸配列(配列番号89)
ADI29340−IgG1
HCのアミノ酸配列(配列番号90)
ADI26630−IgG1
HCのアミノ酸配列(配列番号91)
ADI29341−IgG1
HCのアミノ酸配列(配列番号92)
ADI29349−IgG1
HCのアミノ酸配列(配列番号93)
ADI26591−IgG1
HCのアミノ酸配列(配列番号94)
ADI29371−IgG1
HCのアミノ酸配列(配列番号95)
ADI30793−IgG1
HCのアミノ酸配列(配列番号96)
ADI30794−IgG1
HCのアミノ酸配列(配列番号97)
CD47タンパク質のアミノ酸配列(配列番号56)
本願の「配列表」の項目に、本発明に代表される10種の抗体(ADI-26624, ADI-29336, ADI-29340, ADI-26630, ADI-29341, ADI-29349, ADI-26591, ADI-29371, ADI-30793, ADI-30794)のCDR領域、軽鎖および重鎖可変領域、並びに軽鎖および重鎖のアミノ酸配列と、対応するヌクレオチド配列が列挙される。更に、本発明において上述した典型的抗体の軽鎖、重鎖、軽鎖および重鎖可変領域についての配列番号付けが第1表に示される。
本発明の抗体は酵母細胞中とCHO-S細胞中で発現させ、次いで精製した。
現行手順(WO 2009036379;WO 2010105256; WO 2012009568)に従って、酵母ベースの抗体提示ライブラリー(Adimab)を、各ライブラリーが1×109の多様性になるように増幅させた。簡単に言えば、Miltenyi ComanyからのMACSシステムを使って、最初の2ラウンドのスクリーニングにより磁気活性化細胞選別を行った。1ラウンド目は、該ライブラリーの酵母細胞(〜1×1010細胞/ライブラリー)を別々に、100 nMビオチン標識CD47抗原(Acro Biosystems, カタログ番号CD7-H5227-1 mg)を含有するFACS洗浄緩衝液(0.1%ウシ血清タンパク質を含むリン酸塩緩衝液)中で室温にて15分間インキュベートした。細胞を50 mLの予冷したFACS洗浄緩衝液で洗浄し、次いで40 mLの同洗浄緩衝液中に再懸濁し、そして500μLのストレプトマイシンマイクロビーズ(Miltenyi LS)の添加後、4℃にて15分間インキュベートした。1000 rpmでの5分間の遠心分離により上清を捨て、細胞ペレットを5 mLのFACS洗浄緩衝液中に再懸濁し、その細胞懸濁液をMiltenyi LSカラムに投入した。添加が終了した後、カラムを各洗浄3 mLのFACS洗浄緩衝液で3回洗浄した。Miltenyi LSカラムを磁気領域から取り外し、次いで5 mLの培養培地を用いて溶出させた。溶出した酵母細胞を収集し、37℃で一晩増殖させた。
当該抗体を発現するCHO-S細胞系は、Freedom(登録商標)CHO-S(登録商標)キット(Invitrogen)を使って製造元の指示書に従って確立した。まず、抗体分子の重鎖と軽鎖のDNA配列を同じpCHO1.0プラスミド中に、重鎖が軽鎖の上流にくるように挿入した。作製されたpCHO1.0プラスミドを次いで化学的トランスフェクションとエレクトロポレーションによりCHO細胞系中に導入した。トランスフェクションの48時間後に、ForteBioを使って抗体の収量を検出してトランスフェクション効率を測定した。トランスフェクト細胞を2ラウンドの選択的スクリーニングにかけた後、高い抗体発現率を有する細胞プールを得た。次いで細胞プールを増殖させて抗体を高度に発現させ、細胞上清を収集し、プロテインAカラム上で>95%の抗体純度に精製した。
本発明の上述した10種の典型的抗体の平衡解離定数(KD)を、生物光学干渉法(bio-light interferometry)(ForteBio)アッセイを用いて決定した。
本発明の上記10種の抗体の全てが、当業界で認められている既知の抗CD47抗体であるHu5F9の親和性に匹敵する、非常に高い親和性を呈することが分かる。
フローサイトメトリーに基づいたアッセイにおいて、ヒトCD47への前記10種の典型的な本発明抗体の結合を測定した。
SIRPαへのヒトCD47の結合を遮断する10種の典型的抗体の能力を、フローサイトメトリーにより測定した。
フローサイトメトリーに基づくアッセイにおいて、本発明の抗体(ADI-26624、ADI-29336、ADI-29340、ADI-26630、ADI-29341、ADI-29349、ADI-29371、ADI-30793およびADI-30794)の、マクロファージによる腫瘍細胞の貪食を促進する能力を測定した。
本発明の抗CD47抗体(ADI-26624、ADI-26630、ADI-29340およびADI-29341)の抗腫瘍効果を、NOD/SCIDマウスモデルにおいて試験した。
手順は以下の通りである:
ヒトバーキットリンパ腫Raji細胞(ATCC# CCL-86)はATCCから購入し、その後のインビボ実験のためATCCの必須要件に厳密に従って、規定通りに継代培養した。細胞を遠心分離により採取し、滅菌PBS中に再懸濁し、そして107細胞/mLの細胞密度になるよう調整した。0.1 mLの細胞懸濁液を取り、Matrigelと1:1で混合し、NOD/SCIDマウス(Beijing Vital River Laboratory Animal Technology Co., Ltd.)の右脇腹に皮下接種した。試験期間中週2回、腫瘍と体重を測定した。腫瘍エンドポイントを満たした時またはマウスが>20%の体重減少を示した時、マウスを安楽死させた。接種10日後、実験に適格なマウスを1群あたり8匹の動物で無作為化した。マウスにおける腫瘍体積は、各群において以下の式:(幅)2×長さ/2を用いてキャリパーにより測定され、マウスの各群の最大腫瘍体積は110 mm3であった。
上述の方法により得られたマウスを無作為化し、異なる処置を施した:連続2週間に渡り隔日に1回の投与頻度で、1 mg/kgまたは5 mg/kgのPBS、対照IgG抗体(IgG4)、ベンチマーク(Hu5F9)、並びに本発明の抗体ADI-26624およびADI-26630の腹腔内注射。詳細な分類と投与方法は第3表に示される。
従って、本発明の抗体は腫瘍に対する非常に良好な治療効果を示し、これは対照抗体Hu5F9の治療効果よりも優れていることが分かる。
上記方法により得られたマウスを無作為化し、異なる処置を施した。すなわち、0.5 mg/kgまたは5 mg/kgのPBS、対照IgG抗体(IgG4)並びに本発明の抗体ADI-26630、ADI-29340およびADI-29341の腹腔内注射を連続2週間に渡り2日に1回行った。詳細な分類と投与方法は下の第5表に示される。
大部分の抗CD47抗体は、RBC凝集を促進する副作用を有し、それによりそれらの抗体の治療用途を制限することが従来知られている。従って、本発明者らは更に、本明細書に開示される抗体のRBC凝集を検討した。
新鮮なヒト血液を採取し、PBSで3回洗浄し、10%ヒトRBC懸濁液を調製した。ヒトRBCを96ウェルの丸底プレート中で試験抗体(最大濃度60μg/mL、3倍希釈系列、合計11種の濃度)と共に37℃で2〜6時間インキュベートした。反応終了後、写真撮影し、結果を判断した。結果の判定基準は、赤血球がウェルの底に沈み網目状に広がり、霞のように見える場合にRBC凝集反応が起こったと判定し(図12のHu5F9の結果を参照のこと)そしてRBCがウェルの底に断続的な赤い斑点として沈降するような場合にはRBC凝集反応が起こらないと判定するものである(図12の対照を参照のこと)。
Claims (23)
- 単離された抗CD47モノクローナル抗体またはそれの抗原結合性断片であって、
(i) 配列番号44、45または46に示された重鎖可変領域の3つの相補性決定領域HCDRと、配列番号54に示された軽鎖可変領域の3つの相補性決定領域LCDR;
(ii) 配列番号47、48または49に示された重鎖可変領域の3つの相補性決定領域HCDRと、配列番号55に示された軽鎖可変領域の3つの相補性決定領域LCDR;
(iii) 配列番号50または51に示された重鎖可変領域の3つの相補性決定領域HCDRと、配列番号57に示された軽鎖可変領域の3つの相補性決定領域LCDR;または
(iv) 配列番号52または53に示された重鎖可変領域の3つの相補性決定領域HCDRと、配列番号58に示された軽鎖可変領域の3つの相補性決定領域LCDR
を含む、前記抗体またはそれの抗原結合性断片。 - 単離された抗CD47モノクローナル抗体またはそれの抗原結合性断片であって、重鎖可変領域の3つの相補性決定領域HCDRsと軽鎖可変領域の3つの相補性決定領域LCDRsとを含み、ここでHCDR1が配列番号1, 2, 3, 4, 5, 6, 7, 8, 98または99に示されるアミノ酸配列を含み、HCDR2が配列番号9, 10, 11, 12, 13, 14, 15, 16, 100または101に示されるアミノ酸配列を含み、HCDR3が配列番号17, 18, 19, 20, 21, 22, 102または103に示されるアミノ酸配列を含み、LCDR1が配列番号23または24に示されるアミノ酸配列を含み、LCDR2が配列番号25または26に示されるアミノ酸配列を含み、そしてLCDR3が配列番号27, 28, 29または30に示されるアミノ酸配列を含む、前記抗体またはそれの抗原結合性断片。
- 単離された抗CD47モノクローナル抗体またはそれの抗原結合性断片であって、重鎖可変領域および/または軽鎖可変領域を含み、ここで
前記重鎖可変領域が
(i) 表Bに列挙された抗体のいずれか1つのVH中に含まれる3つの相補性決定領域(HCDRs);
(ii) 表Aに示されるHCDR1、HCDR2およびHCDR3の組み合わせ;
(iii) HCDR1、HCDR2およびHCDR3であって、HCDR1が配列番号1, 2, 3, 4, 5, 6, 7, 8, 98または99に示されるアミノ酸配列を含み、HCDR2が配列番号9, 10, 11, 12, 13, 14, 15, 16, 100または101に示されるアミノ酸配列を含み、HCDR3が配列番号17, 18, 19, 20, 21, 22, 102または103に示されるアミノ酸配列を含み;または
(iv) 前記3つのCDR領域中に少なくとも1アミノ酸でかつ多くても5アミノ酸のアミノ酸置換(例えば保存的置換)、欠失もしくは挿入を含む、前記(i)〜(iii)に記載のHCDRの変異体
を含み;そして/または
前記軽鎖可変領域が
(i) 表B中に列挙された抗体のいずれか1つのVL中に含まれる3つの相補性決定領域(LCDRs);
(ii) 表A中に示されるLCDR1、LCDR2およびLCDR3の組み合わせ;
(iii) LCDR1、LCDR2およびLCDR3であって、LCDR1が配列番号23または24に記載のアミノ酸配列を含み、LCDR2が配列番号25または26に示されるアミノ酸配列を含み、そしてLCDR3が配列番号27、28、29または30に示されるアミノ酸配列を含み;または
(iv) 前記3つのCDR領域中に少なくとも1アミノ酸でかつ多くても5アミノ酸のアミノ酸置換(例えば保存的置換)、欠失もしくは挿入を含む、前記(i)〜(iii)に記載のLCDRの変異体
を含む、前記抗体またはそれの抗原結合性断片。 - (i) 配列番号44、45または46に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む重鎖可変領域、および/または配列番号54に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む軽鎖可変領域;または
(ii) 配列番号47、48または49に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む重鎖可変領域、および/または配列番号55に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む軽鎖可変領域;または
(iii) 配列番号50または51に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む重鎖可変領域、および/または配列番号57に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む軽鎖可変領域;または
(iv) 配列番号52または53に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む重鎖可変領域、および/または配列番号58に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む軽鎖可変領域
を含む、請求項1〜3のいずれか一項に記載の単離されたモノクローナル抗体またはそれの抗原結合性断片。 - (i) 配列番号74、76、77、88、89または90に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む重鎖、および/または配列番号75に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む軽鎖;または
(ii) 配列番号78、80、81、91、92または93に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む重鎖、および/または配列番号79に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む軽鎖;または
(iii) 配列番号82、84、94または95に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む重鎖、および/または配列番号83に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む軽鎖;または
(iv) 配列番号85、87、96または97に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む重鎖、および/または配列番号86に示されるアミノ酸配列に対し少なくとも90%の配列同一性を有するアミノ酸配列を含む軽鎖
を含む、請求項1〜4のいずれか一項に記載の単離されたモノクローナル抗体またはそれの抗原結合性断片。 - 前記抗体がヒト化抗体またはヒト抗体である、請求項1〜5のいずれか一項に記載の単離されたモノクローナル抗体またはそれの抗原結合性断片。
- 前記抗原結合性断片がFab、Fab’-SH、Fv、scFv、または(Fab’)2断片からなる群より選択される、請求項1〜6のいずれか一項に記載の単離されたモノクローナル抗体またはそれの抗原結合性断片。
- フレームワーク配列を含み、該フレームワーク配列の少なくとも一部分がヒトコンセンサスフレームワーク配列である、請求項1〜7のいずれか一項に記載の単離されたモノクローナル抗体またはそれの抗原結合性断片。
- CD47の結合に対して請求項1〜8のいずれか一項に記載の抗体と競合するか、あるいは請求項1〜8のいずれか一項に記載の抗体へのCD47の結合と拮抗するおよび/または遮断する、抗CD47モノクローナル抗体またはそれの抗原結合性断片。
- 請求項1〜9のいずれか一項に記載の単離された抗CD47モノクローナル抗体またはそれの抗原結合性断片をコードする、単離された核酸。
- 請求項10に記載の核酸を含むベクターであって、好ましくは発現ベクターである、ベクター。
- 請求項11に記載のベクターを含む宿主細胞であって、好ましく原核細胞または真核細胞であり;より好ましくは酵母細胞、哺乳類細胞、または抗体もしくはそれの抗原結合性断片を調製するのに適当である他の細胞からなる群より選択され、好ましくはCHO細胞または293細胞である、宿主細胞。
- 抗CD47モノクローナル抗体またはそれの抗原結合性断片の調製方法であって、請求項1〜9のいずれか一項に記載の抗CD47モノクローナル抗体またはそれの抗原結合性断片をコードする核酸を発現させるのに適当である条件下で、請求項12に記載の宿主細胞を培養し、場合により前記モノクローナル抗体またはそれの抗原結合性断片を単離することを含み、そして場合により前記宿主細胞から前記抗CD47モノクローナル抗体またはそれの抗原結合性断片を回収することを更に含む、方法。
- 請求項13に記載の方法により調製された抗CD47モノクローナル抗体またはそれの抗原結合性断片。
- 請求項1〜9および14のいずれか一項に記載の抗CD47抗体またはそれの抗原結合性断片と、場合により医薬担体とを含む、医薬組成物。
- 請求項1〜9および14のいずれか一項に記載の抗CD47抗体もしくはそれの抗原結合性断片の有効量または請求項15に記載の医薬組成物の有効量を対象に投与することを含む、対象においてマクロファージ貪食作用を促進する方法。
- 請求項1〜9および14のいずれか一項に記載の抗CD47抗体もしくはそれの抗原結合性断片の有効量または請求項15に記載の医薬組成物の有効量を対象に投与することを含む、対象において癌または腫瘍を治療する方法。
- 癌または腫瘍の症状を緩和する方法であって、それを必要とする対象に、請求項1〜9および14のいずれか一項に記載の抗CD47抗体もしくはそれの抗原結合性断片の有効量または請求項15に記載の医薬組成物の有効量を投与することを含む、方法。
- 前記対象がヒトである、請求項16〜18のいずれか一項に記載の方法。
- 前記癌または腫瘍が様々な血液学的腫瘍および固形腫瘍、例えば急性骨髄性白血病(AML)、慢性骨髄性白血病(CML)、急性リンパ球性白血病(ALL)、慢性リンパ球性白血病(CLL)、非ホジキンリンパ腫(NHL)、多発性骨髄腫(MM)、リンパ腫、乳癌、頭頸部癌、胃癌、肺癌、食道癌、腸癌、卵巣癌、頸癌、肝癌、腎臓癌、膵臓癌、膀胱癌、結腸直腸癌、神経膠腫、黒色腫および他の固形腫瘍である、請求項17または18に記載の方法。
- 1以上の他の医薬の有効量を前記対象に投与することを更に含み、ここで前記他の医薬が例えば、T細胞による認識を通して腫瘍細胞を攻撃する様々なモノクローナル抗体医薬、例えばリツキシマブ、セツキシマブおよびトラスツズマブである、請求項16〜18のいずれか一項に記載の方法。
- 試料中のCD47タンパク質の存在を検出する方法であって、
(a) 該試料を請求項1〜9および14のいずれか一項に記載の抗体またはそれの抗原結合性断片と接触させ;そして
(b) 前記抗体またはそれの抗原結合性断片とCD47タンパク質との間の複合体の形成を検出する
ことを含む、前記方法。 - 腫瘍療法の効果を測定する方法であって、該療法の前後に対象からの試料中のCD47発現癌細胞の数を決定し、ここで該療法後のCD47発現癌細胞の数の減少が該療法が効果的であることを示す、方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021041193A JP2021094028A (ja) | 2017-08-29 | 2021-03-15 | 抗cd47抗体およびその使用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710759828.9 | 2017-08-29 | ||
CN201710759828.9A CN109422811A (zh) | 2017-08-29 | 2017-08-29 | 抗cd47抗体及其用途 |
PCT/CN2018/102752 WO2019042285A1 (zh) | 2017-08-29 | 2018-08-28 | 抗cd47抗体及其用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021041193A Division JP2021094028A (ja) | 2017-08-29 | 2021-03-15 | 抗cd47抗体およびその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020508645A true JP2020508645A (ja) | 2020-03-26 |
JP6923658B2 JP6923658B2 (ja) | 2021-08-25 |
Family
ID=65503903
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019541431A Active JP6923658B2 (ja) | 2017-08-29 | 2018-08-28 | 抗cd47抗体およびその使用 |
JP2021041193A Pending JP2021094028A (ja) | 2017-08-29 | 2021-03-15 | 抗cd47抗体およびその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021041193A Pending JP2021094028A (ja) | 2017-08-29 | 2021-03-15 | 抗cd47抗体およびその使用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11292836B2 (ja) |
EP (1) | EP3546482A4 (ja) |
JP (2) | JP6923658B2 (ja) |
KR (2) | KR102316241B1 (ja) |
CN (3) | CN109422811A (ja) |
AU (1) | AU2018325845B2 (ja) |
BR (1) | BR112019014694A2 (ja) |
CA (1) | CA3048578A1 (ja) |
WO (1) | WO2019042285A1 (ja) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109422811A (zh) * | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
MX2020005463A (es) | 2017-12-01 | 2020-09-07 | Seattle Genetics Inc | Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer. |
CN109970860A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
US20200400662A1 (en) | 2019-06-07 | 2020-12-24 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
KR20220024211A (ko) | 2019-06-19 | 2022-03-03 | 레푸 바이오파마 컴퍼니 리미티드 | 항-cd47 항체 및 그것의 사용 |
CN114040777A (zh) * | 2019-06-25 | 2022-02-11 | 信达生物制药(苏州)有限公司 | 包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途 |
CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
CN110256565B (zh) * | 2019-08-02 | 2021-03-23 | 天津大学 | 抗cd47纳米抗体突变体及其应用 |
CN112969715B (zh) * | 2019-08-21 | 2022-03-18 | 和铂医药(上海)有限责任公司 | 一种抗cd47抗原结合蛋白及其应用 |
KR20220085796A (ko) | 2019-10-18 | 2022-06-22 | 포티 세븐, 인코포레이티드 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
KR20220103959A (ko) * | 2019-10-25 | 2022-07-25 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 항-cd47 항체 및 그 용도 |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
CN113004406B (zh) * | 2019-12-20 | 2022-04-26 | 广东菲鹏制药股份有限公司 | 抗cd47抗体及其应用 |
KR20220131918A (ko) | 2019-12-24 | 2022-09-29 | 카나 바이오사이언스, 인코포레이션 | 다이아실글리세롤 키나제 조절 화합물 |
EP4089114A1 (en) * | 2020-01-09 | 2022-11-16 | Innovent Biologics (Suzhou) Co., Ltd. | Application of combination of anti-cd47 antibody and anti-cd20 antibody in preparation of drugs for preventing or treating tumors |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
CN111454359B (zh) * | 2020-03-23 | 2021-06-29 | 倍而达药业(苏州)有限公司 | Cd47抗体或其免疫活性片段及应用 |
CN113461817A (zh) * | 2020-03-31 | 2021-10-01 | 苏州泽璟生物制药股份有限公司 | 一种抗人cd47抗体及其抗原结合片段、制备方法和应用 |
JP2023519620A (ja) | 2020-04-02 | 2023-05-11 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Cd47に結合する抗原結合ポリペプチド及び用途 |
WO2022007947A1 (zh) * | 2020-07-10 | 2022-01-13 | 信达生物制药(苏州)有限公司 | 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途 |
CN114230662A (zh) * | 2020-09-09 | 2022-03-25 | 安源医药科技(上海)有限公司 | 抗cd47抗体及其用途 |
US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
US20240076412A1 (en) * | 2021-01-05 | 2024-03-07 | National Institute Of Biological Sciences, Beijing | A bispecific antibody targeting gpc3 and cd47 |
TW202233694A (zh) | 2021-02-07 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 雙特異性抗體 |
EP4296282A1 (en) | 2021-02-19 | 2023-12-27 | SHAPERON Inc. | Single domain antibody against cd47 and use thereof |
US20240132627A1 (en) | 2021-02-19 | 2024-04-25 | Shaperon Inc. | Bispecific single domain antibody to pd-l1 and cd47 and use thereof |
AU2022235341A1 (en) | 2021-03-12 | 2023-09-21 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN115785268A (zh) * | 2021-09-13 | 2023-03-14 | 三优生物医药(上海)有限公司 | 抗cd47抗体及其用途 |
CN115957339A (zh) | 2021-09-16 | 2023-04-14 | 正大天晴药业集团股份有限公司 | 抗体药物偶联物及其组合物和用途 |
CN118055947A (zh) | 2021-09-30 | 2024-05-17 | 正大天晴药业集团南京顺欣制药有限公司 | 联合治疗血液肿瘤的抗cd47抗体 |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
CN114560943B (zh) * | 2022-02-28 | 2022-12-16 | 先进生物(苏州)有限公司 | Cd7-car-t细胞及其制备方法和应用 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2023224412A1 (ko) | 2022-05-19 | 2023-11-23 | (주)샤페론 | Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도 |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
CN116731175B (zh) * | 2023-05-19 | 2024-03-08 | 四川大学 | 一种抗cd47的纳米抗体及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044857A1 (ja) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | ヒト化抗cd47抗体 |
JP2013534409A (ja) * | 2010-05-14 | 2013-09-05 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | Cd47に対するヒト化及びキメラモノクローナル抗体 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP2695896B1 (en) | 2006-10-06 | 2018-08-22 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Prevention of tissue ischemia, related methods and compositions |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
CA2711370C (en) * | 2008-01-15 | 2017-06-13 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
ES2740823T3 (es) | 2008-01-15 | 2020-02-06 | Univ Leland Stanford Junior | Métodos para manipular fagocitosis mediada por CD47 |
EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
EP2340034B2 (en) | 2008-08-07 | 2019-02-13 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Radioprotectants targeting thrombospondin-1 and cd47 |
CA2771336C (en) | 2009-09-15 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
AU2011279073B2 (en) | 2010-07-16 | 2016-06-09 | Adimab, Llc | Antibody libraries |
PL2812443T3 (pl) | 2012-02-06 | 2020-01-31 | Inhibrx, Inc. | Przeciwciała CD47 i sposoby ich zastosowania |
PT2925782T (pt) | 2012-12-03 | 2020-04-22 | Novimmune Sa | Anticorpos anti-cd47 e métodos de utilização destes |
US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
BR112015013431A2 (pt) | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
HUE047221T2 (hu) * | 2012-12-17 | 2020-04-28 | Trillium Therapeutics Inc | A CD47+ kóros sejtek kezelése SIRP alfa-FC fúziókkal |
ES2944477T3 (es) | 2013-02-06 | 2023-06-21 | Inhibrx Inc | Anticuerpos CD47 no reductores de plaquetas y no reductores de glóbulos rojos y métodos de uso de los mismos |
CN103665165B (zh) | 2013-08-28 | 2016-02-24 | 江苏匡亚生物医药科技有限公司 | 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途 |
US11046763B2 (en) * | 2014-01-08 | 2021-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
NZ740686A (en) | 2015-09-18 | 2021-12-24 | Arch Oncology Inc | Therapeutic cd47 antibodies |
CA2999277A1 (en) * | 2015-09-21 | 2017-03-30 | Surface Oncology, Inc. | Anti-cd47 antibodies and methods of use |
CN106084052B (zh) * | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
CN106117354B (zh) | 2016-06-24 | 2020-01-14 | 安徽未名细胞治疗有限公司 | 一种全人源抗CD47的全分子IgG抗体及其应用 |
CN109422811A (zh) * | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
WO2019129054A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
CN110305212A (zh) * | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
-
2017
- 2017-08-29 CN CN201710759828.9A patent/CN109422811A/zh active Pending
-
2018
- 2018-08-28 JP JP2019541431A patent/JP6923658B2/ja active Active
- 2018-08-28 KR KR1020197022094A patent/KR102316241B1/ko active IP Right Grant
- 2018-08-28 US US16/473,867 patent/US11292836B2/en active Active
- 2018-08-28 CA CA3048578A patent/CA3048578A1/en active Pending
- 2018-08-28 AU AU2018325845A patent/AU2018325845B2/en active Active
- 2018-08-28 WO PCT/CN2018/102752 patent/WO2019042285A1/zh unknown
- 2018-08-28 KR KR1020217033457A patent/KR102389083B1/ko active IP Right Grant
- 2018-08-28 BR BR112019014694A patent/BR112019014694A2/pt unknown
- 2018-08-28 CN CN202211194838.XA patent/CN116410316A/zh active Pending
- 2018-08-28 CN CN201880005949.7A patent/CN110214154B/zh active Active
- 2018-08-28 EP EP18849790.3A patent/EP3546482A4/en active Pending
-
2021
- 2021-03-15 JP JP2021041193A patent/JP2021094028A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005044857A1 (ja) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | ヒト化抗cd47抗体 |
JP2013534409A (ja) * | 2010-05-14 | 2013-09-05 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | Cd47に対するヒト化及びキメラモノクローナル抗体 |
Also Published As
Publication number | Publication date |
---|---|
AU2018325845A1 (en) | 2019-07-11 |
WO2019042285A1 (zh) | 2019-03-07 |
CA3048578A1 (en) | 2019-03-07 |
BR112019014694A2 (pt) | 2020-04-07 |
KR102389083B1 (ko) | 2022-04-22 |
JP2021094028A (ja) | 2021-06-24 |
KR102316241B1 (ko) | 2021-10-22 |
CN109422811A (zh) | 2019-03-05 |
CN110214154B (zh) | 2022-10-21 |
EP3546482A4 (en) | 2020-10-21 |
JP6923658B2 (ja) | 2021-08-25 |
KR20210129259A (ko) | 2021-10-27 |
AU2018325845B2 (en) | 2020-11-26 |
EP3546482A1 (en) | 2019-10-02 |
US11292836B2 (en) | 2022-04-05 |
CN116410316A (zh) | 2023-07-11 |
CN110214154A (zh) | 2019-09-06 |
KR20190105024A (ko) | 2019-09-11 |
US20200181259A1 (en) | 2020-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6923658B2 (ja) | 抗cd47抗体およびその使用 | |
CN111630068B (zh) | 抗cd47抗体及其用途 | |
JP7461741B2 (ja) | 抗pd-l1およびil-2サイトカイン | |
KR102536145B1 (ko) | 항-pd-1 항체 및 이의 용도 | |
CN105392800B (zh) | 抗cxcl1、cxcl7和cxcl8抗体及其应用 | |
TWI432452B (zh) | 針對her-3之抗體類及其用途 | |
WO2018177220A1 (zh) | 抗ox40抗体及其用途 | |
US20150037323A1 (en) | Humanized axl antibodies | |
TW201920279A (zh) | B7-h4抗體及其使用方法 | |
KR101838310B1 (ko) | 암의 치료를 위한 인간화 항-cxcr4 항체들 | |
KR102405278B1 (ko) | Alk7 결합 단백질 및 이들의 용도 | |
TWI756621B (zh) | 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體 | |
KR20210005169A (ko) | 최적화된 항tl1a 항체 | |
EP2270053A1 (en) | Humanized AXL antibodies | |
TW201946658A (zh) | 抗gitr抗體及其用途 | |
KR20220016136A (ko) | Alk7 결합 단백질 및 이의 용도 | |
WO2023145844A1 (ja) | 抗ヒトcxcl1抗体 | |
TW202411252A (zh) | 抗pd-1抗體及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190828 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190828 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201102 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20201117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210315 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210315 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210318 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210510 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210511 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210607 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210629 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210729 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6923658 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |